Cyclooxygenase (COX) catalyzes the conversion of arachidonic acid into prostaglandins (PGs), which play a significant role in health and disease in the gastrointestinal tract (GI) and in the renal, skeletal, and ocular systems. COX-1 is constitutively expressed and found in most normal tissues, whereas COX-2 can be expressed at low levels in normal tissues and is highly induced by pro-inflammatory mediators. Inhibitors of COX activity include: (1) conventional nonselective, nonsteroidal anti-inflammatory drugs (ns-NSAIDs) and (2) COX-2 selective nonsteroidal antiinflammatory drugs (COX-2 s-NSAIDs). Inhibition of COX-1 often elicits GI toxicity in animals and humans. Therefore, COX-2 s-NSAIDs were developed to provide a selective COX-2 agent, while minimizing the attendant COX-1-mediated GI toxicities. Rats and dogs overpredict COX inhibition for renal effects such as renal handling of electrolytes in humans. COX inhibitors are shown to have both beneficial and detrimental effects, such as on healing of ligament or tendon tears, on the skeletal system in animal models. Certain ophthalmic conditions such as glaucoma and keratitis are associated with increased COX-2 expression, suggesting a potential role in their pathophysiology.
INTRODUCTION
Cyclooxygenase (COX) has two distinct membraneanchored isoenzymes, COX-1 and COX-2. COX-1 is constitutively expressed and found in most normal tissues throughout the body; COX-2 is expressed in normal tissues at low levels and is highly induced by pro-inflammatory mediators in the setting of inflammation, injury, and pain. Following exogenous stimuli (e.g., inflammation), arachidonic acid (AA) is liberated by phospholipases. Both COX-1 and COX-2 then catalyze the conversion of AA into various prostaglandins (PG), which is illustrated in more detail in Figure 1 (Radi and Khan 2008) . In this critical review, the comparative cellular expression and distribution of COX-1 and COX-2 and the pathophysiologic role of COXs and subsequent effects associated with COX inhibition in animal models are explored in the gastrointestinal tract (GI) and in the skeletal, ocular, and renal systems. mice are normal except for a decrease in intestinal PGE 2 levels (Sigthorsson et al. 2002) . COX-1 inhibition alone does not cause GI injury. A selective COX-1 inhibitor (SC-560) did not cause intestinal damage in rats (Tanaka, Araki et al. 2002) .
In dogs, no evidence for GI toxicity has been observed with the COX-2 selective NSAID celecoxib at supertherapeutic doses (Khan et al. 1997 ). A recent s-NSAID, firocoxib, has been clinically proven to control osteoarthritis (OA) pain and inflammation in dogs (Pollmeier et al. 2006; Ryan et al. 2006 ). FIGURE 1.-Prostaglandins' (PGs') role in the gastrointestinal tract (GI) in health, disease, and effects of ns-NSAIDs and s-NSAIDs. Following an exogenous stimulus (e.g., inflammation), cell membrane phospholipid is liberated to arachidonic acid (AA) by phospholipase A 2 . Both COX-1 and COX-2 catalyze the conversion of AA into various PGs. COX-1 is the predominant isoform in the normal GI (gastric fundus, corpus, antrum and/or pylorus, duodenum, jejunum, ileum, cecum, and colon), whereas COX-2 expression is up-regulated during inflammatory or neoplastic conditions. Nonselective NSAIDs (e.g., carprofen, etodolac, flunixin meglumine, ketoprofen, indomethacin, and phenylbutazone) inhibit COX-1 and COX-2, whereas selective sNSAIDs (e.g., celecoxib, firocoxib, rofecoxib, lumiracoxib, valdecoxib) spare COX-1 and inhibit only COX-2. Potential mechanisms of ns-NSAID-mediated GI toxicity include: (1) increased intestinal epithelial permeability, (2) uncoupling of mitochondrial oxidative phosphorylation, (3) gastric hypermotility, (4) decreased epithelial cell secretion of bicarbonates, (5) decreased mucin secretion, (6) decreased blood flow, (7) decreased neutral pH of mucosa, (8) leukocyte infiltration, and (8) TLR-4/MyD88-dependent into the GI mucosa after injury. Loss of these GI-protective mechanisms can lead to GI erosion, ulcers, bleeding, and perforation. No adverse GI, hematological, or serum biochemical adverse effects were seen after oral daily administration of firocoxib for twenty-nine days in healthy dogs (Steagall et al. 2007 ). In a large study with more than 1000 dogs with OA, a small withdrawal rate of 2.9% resulting from firocoxib GI-associated effects was observed, and no serious drug-related adverse events were reported (Ryan et al. 2006) . The overall clinical efficacy of firocoxib to treat OA in horses was comparable to the ns-NSAID, phenylbutazone (Doucet et al. 2008) . In rats, celecoxib did not induce any damage to healthy stomachs or gastrointestinal mucosa (Altinkaynak et al. 2003; Li et al. 2003) , did not alter the gastric mucosal barrier (Coppelli et al. 2004) , did not cause intestinal ulcers, and reduced the severity of experimental colitis (Cuzzocrea et al. 2001) . However, celecoxib has been reported to exacerbate inflammation-associated colonic injury in experimental colitis in the rat (Zhang et al. 2004 ).
Pathophysiology and Mechanisms of COX Inhibitor-associated GI Toxicity
GI associated toxicity seen with ns-NSAIDs may be attributed to direct, nonspecific irritation or to various biochemical and pharmacological mechanisms linked to local COX inhibition (Hawkey and Skelly 2002) (Figure 1 ). The gastric and duodenal mucosa are rich in PGs, which play a protective role in the GI via adequate perfusion of the gastroduodenal mucosa, epithelial cell secretion of bicarbonate, secretion of mucus, and maintenance of a neutral mucosa pH (Elliott et al. 1996; Scheiman et al. 1996) . Cyclooxygenase inhibition is suggested to increase susceptibility of the gastric mucosa to injury by inhibiting secretion of the cytoprotective mucus and bicarbonate and altering the physicochemical nature of mucus (Kauffman 1989) . Studies in animals suggest that inhibition of COX-1 and COX-2 is required for induction of gastric ulcerogenic action of ns-NSAIDs (Tanaka et al. 2001; Tanaka, Araki et al. 2002; Takeuchi et al. 2004; Wallace et al. 2000) . For example, in an experimental mouse model, ulcers of the small intestine were observed when celecoxib, an s-NSAID, and SC-560, a selective COX-1 inhibitor, Location of injury similar with both ns-NSAIDs and s-NSAIDs, with the exception that injuries with s-NSAIDs occur at high exposure multiples. b Injury to lower GI uncommon in monkeys. FIGURE 2.-Severe indomethacin-induced gastric mucosal hemorrhage and ulceration at the gastro-duodenal junction (arrows) in a dog. were administered concurrently, but no GI damage was observed when either compound was administered independently (Sigthorsson et al. 2002) . Other likely contributors to the increased susceptibility of the GI to ulcerogenicity of nsNSAIDs, in addition to inhibition of PG synthesis and abrogation of protective mechanisms (Hawkey and Skelly 2002) , include stress factors, decreased mucosal resistance in the diseased state (Rainsford 1982) , decreased cytokine production, inhibition of lipooxygenase, neutrophil adherence, and direct chemical damage of the GI (Johnston and Budsberg 1997) . Toll-like receptor (TLR) 4 has recently been implicated in ns-NSAID (indomethacin)-induced small intestine damage because TLR4 -/ -and MyD88 -/ -mice showed resistance to ns-NSAID-induced small intestinal damage (Watanabe et al. 2008) .
Other mechanisms potentially involved in the pathogenesis of ns-NSAID-associated GI toxicity in animal models include: (1) elevation in enteric bacterial numbers and epithelial permeability of the small intestine associated with enterohepatically recirculated ns-NSAIDs (Reuter et al. 1997) ; (2) infiltration of neutrophils into the mucosa in response to initial tissue injury (Reuter et al. 1997) ; (3) uncoupling of mitochondrial oxidative phosphorylation, leading to increased intestinal permeability and calcium release into the cytosol (Mahmud et al. 1996; Mathews 1996; Somasundaram et al. 2000) ; (4) gastric hypermotility (implicated in indomethacin-treated rats) (Takeuchi et al. 2004) : and (5) TLR-4/MyD88-dependent mechanisms (Watanabe et al. 2008) .
Although ns-NSAID-associated GI toxicity is prevalent throughout species, there are significant interspecies efficacy and toxicity differences (Mahmud et al. 1996) . For example, susceptibility of cats, dogs, and horses to the adverse effects of ns-NSAIDs is greater than that of humans (Mahmud et al. 1996) . Dogs are less tolerant to ns-NSAIDs than rats or humans and more at risk for ns-NSAID-induced gastropathy (Elliott et al. 1988; Forsyth et al. 1998) . However, dogs tolerate ns-NSAIDs better than cats. Since cats lack the glucuronyl transferase enzyme, they are delicately sensitive to the adverse effects of drugs that are glucuronidated before elimination (i.e., acetaminophen) (Court and Greenblatt 1997) . Naproxen is well tolerated by mice, rabbits, monkeys, and pigs, tolerated less by rats, and poorly tolerated by dogs (Hallesy et al. 1973) .
In summary, there appear to be significant interspecies differences in both the level of COX-1 expression and the ratio of COX-1 and COX-2 expression and susceptibility to toxicity with COX inhibition in the GI. When compared to ns-NSAIDs, COX-2 s-NSAIDs have an improved GI tolerability profile.
CYCLOOXYGENASES IN BONE, TENDON, AND LIGAMENT HEALING

The Process of Bone Healing and Potential Role of Prostaglandins
Prostaglandins (PGs) play a significant role in and are known modulators of tissue metabolism including bone, ligaments, and tendons via the action of osteoclasts and osteoblasts. PGE 2 is the most abundant PG produced by osteoblasts and has been demonstrated to play a critical role in bone-to-bone formation, woven bone formation, and bone resorption, primarily through the EP 2 and EP 4 PG receptor subtypes (Radi and Khan 2005) . To better understand the role of PGs in the process of bone healing and the effects of ns-NSAIDs and COX-2 s-NSAIDs on this dynamic process, it is important to understand the pathophysiology of bone healing and PG contributions to this process. Figure 4 illustrates the major phases of bone healing where PGs have the greatest effect in inflammatory response (Radi and Khan 2005) .
COX-1 and COX-2 Expression in Normal Bone, During Repair, and in Pathological Conditions
Expression of COX-1 and COX-2 in normal bone cells, during repair, and in pathological conditions is summarized in Table 3 . COX-1 is mainly expressed in normal bone, whereas COX-2 expression is up-regulated during the initial stages of the bone repair process, or in cases of inflammation or under neoplastic bone conditions.
EFFECTS OF COX INHIBITORS ON BONE, TENDON, AND LIGAMENT HEALING
Nonselective NSAIDs are effective anti-inflammatory drugs that have been used for the treatment of various orthopedic conditions and are not associated with adverse effects on normal bones or joints. ns-NSAIDs have been evaluated in preclinical models of bone healing following fracture, osteotomy, or other surgical procedures. Preclinical models revealed that ns-NSAIDs and COX-2 s-NSAIDs could impair bone, tendon, and ligament healing. Results from multiple studies in various species are variable and show conflicting results on the degree and effects of these agents. For example, treatment with ns-NSAIDs (e.g., aspirin, diclofenac, ibuprofen, indomethacin, and tenoxicam) was associated with impaired bone healing in rats and rabbits (Allen et al. 1980; Altman et al. 1995; Beck et al. 2003; Brown et al. 2004; Giordano et al. 2003; Jaffré et al. 2003; Keller et al. 1987; Lindholm and Tornkvist 1981; Pablos et al. 2008 ). In contrast, quantitative histomorphometric indices of bone formation and resorption, as well as cartilage histology, were not significantly different between indomethacin-treated and nontreated rats (Boiskin et al. 1988) . In a randomized placebo-controlled crossover study in mongrel dogs, indomethacin and phenylbutazone did not affect bone healing (Mbugua et al. 1989) . Treatment with ns-NSAIDs in experimental animal models has shown variable intra-and interspecies effects on tendon and ligament healing (Radi and Khan 2005) .
The effect of COX-2 s-NSAIDs on bone healing is undetermined owing to variable and contrasting study results. A large body of experimental data has been generated in COX-2 knockout mice, but it is unreplicatable in humans or other animal models and is therefore questionable. Effects noted in COX-2 knockout mice included alterations of intramembranous and endochondral bone formation, suggesting a possible role of COX-2 in osteoblast and osteoclast formation, and 38 CYCLOOXYGENASE INHIBITION PATHOPHYSIOLOGY TOXICOLOGIC PATHOLOGY osteoclastogenesis, as indicated by in vitro bone marrow cell cultures (Li et al. 2000; Ono et al. 2003; Zhang et al. 2002) . However, bones of COX-2 knockout mice had no gross or histological bone abnormalities in a separate study . Similar to studies with ns-NSAIDs, variable results were noted with COX-2 s-NSAIDs. For example, studies in rats and/or rabbits have suggested impaired bone healing with celecoxib and rofecoxib, as evidenced by delayed fracture healing, reduced intramembranous and endochondral bone formation, reduced fracture callus mechanical properties, decreased osteoblastogenesis and osteoclastogenesis, persistence of mesenchyme and cartilage in the callus, increased proportion of nonunions, lower fracture load values, or absence of cartilage in the fracture callus, and reduced bony in-growth (Gerstenfeld et al. 2007; Goodman et al. 2002; Karachalios et al. 2007; Simon et al. 2002; Simon and O'Connor 2007; FIGURE 4 .-The sequence of events that occurs during the process of bone healing. Immediately after bone fracture, hemorrhage with subsequent hematoma formation and osteocyte necrosis due to hypoxia (A). This is followed by an inflammatory response in which various inflammatory cells (e.g., macrophages), prostaglandins, cytokines (e.g., IL-6, TNF), and growth factors (e.g., FGF, PDGF) are released with fibrin mesh formation (B). Later on, granulation tissue formation occurs, with fibroblast and mesenchymal cell migration and new capillary formation (C). Bone resorption is then followed by cartilage and callus bone formation (D and E). In this process, osteoid extracellular matrix (ECM) and matrix mineralization occurs. Finally, bone formation and remodeling occurs (F). Zhang et al. 2001; Zhang et al. 2002) . However, celecoxib did not significantly inhibit the rate of spinal fusion in rats and rabbits (Brown et al. 2004 ). DFU, a COX-2 s-NSAID, did not disrupt the mechanism of woven bone remodeling in rats, but altered its timing (Gregory and Forwood 2007) . COX-2 s-NSAIDs have not been widely evaluated in models of ligament and tendon healing. In a rat model of achilles tendon transaction, parecoxib showed an adverse effect on early tendon repair (postinjury days 1-5), but showed improved tendon remodeling when given during later stages of repair (days 6-14) (Marsolais et al. 2003) . When given throughout the healing phase, celecoxib improved the outcome after achilles tendon transection in rats (Yuan et al. 2003) . Therefore, these results do suggest that ns-NSAIDs and COX-2 s-NSAIDs may have some effect on bone fracture healing that is apparent in the earlier stages of the healing process, but bears no significant impact on the overall long-term healing of the fracture (Brown et al. 2004; Gerstenfeld et al. 2003; Ho et al. 1998 ).
PATHOPHYSIOLOGIC ROLE OF PGS AND CYCLOOXYGENASES IN BONE, TENDON, AND LIGAMENT HEALING
The skeleton is a metabolically active organ that undergoes continuous remodeling throughout life. Osteoblasts and osteoclasts, the most important contributors to bone remodeling, produce PGs, which are shown to modulate their function in normal bone metabolism and in bone healing (Gajraj et al. 2003; Li et al. 2002; Okada et al. 2000; Okada et al. 2003; Raisz et al. 2001 ). For example, in an in vitro model using rat femora, changes in PG synthesis and concentration were correlated with changes in the quantity of trabecular regeneration and acceleration of bone healing (Sun et al. 1999) .
PGE 2 is the most abundant PG produced by osteoblastic cells and plays many roles in bone metabolism. PGE 2 interacts with four receptor subtypes (EP 1 R, EP 3 R, EP 2 R, and EP 4 R), of which the latter two are shown to stimulate bone formation and bone resorption, as demonstrated in rat bone tissue and osteoblastic cells (Feyen et al. 1984; Jee et al. 1997; Kawaguchi et al. 1995; Lin et al. 1995; Suzawa et al. 2000; Wadleigh and Herschman 1999; Weinreb et al. 2001) . PGE 2 has also been shown to add bone-to-bone envelopes and to induce woven bone formation (Jee et al. 1997) . Systemic administration of PGE 2 stimulated bone formation and increased bone mass in infants and animals (Marks et al. 1988; Ringel et al. 1982; Suponitzky et al. 1998; Tian et al. 2008; Yang et al. 1993) . PGE 2 infusion in rabbits increased blood flow to the bone, bone marrow, and muscle of the lower limbs, except in the osteotomy area (Keller et al. 1991) . In addition, PGE 2 caused a dose-dependent stimulation of callus formation in rabbits (Keller et al. 1993) . In dogs, administration of PGE 2 increased the extent of mineralization on the bone surface of healing ribs, osteoid formation in all three envelopes, and resorption surface in the cortical endosteal envelope, indicating accelerated remodeling (Norrdin and Shih 1988; Shih and Norrdin 1986) .
The roles of PGs in metabolism translate to bone healing. In the inflammatory stage of healing, PGs, particularly PGE 2 , are abundantly produced by osteoblasts and accumulate in the fracture callus, creating a rich microenvironment of PG activity (Gajraj et al. 2003; Radi and Khan 2005) . PGE 2 , PGI 2 , and TxA 2 then stimulate bone resorption via increased activity of osteoclasts (Forwood 1996; Raisz et al. 1999; Yang et al. 1993) , followed by bone remodeling/formation. The production of PGs in bone has been enhanced indirectly by COX-2 induction (Raisz et al. 1999; Tai et al. 1997) .
The mechanism of COX effects is debatable but may be related to marked reductions in PGE 2 and osteoblastic proliferation with or without PG inhibition. Results from animal models do suggest that ns-NSAIDs and COX-2 s-NSAIDs may have a minimal effect on bone, tendon, and ligament healing, especially at earlier stages, but bear no significant impact on the long-term outcome. In the only direct comparison of a ns-NSAID and a COX-2 s-NSAID, both compounds improved mechanical strength in the later phase of healing (Riley et al. 2001) .
In summary, (1) results from preclinical studies on the effects on COX inhibition on the skeletal system are highly variable; (2) there are intra-and interspecies dose and sensitivity differences; (3) undefined compensating systemic and local factors after COX inhibition may regulate bone repair; (4) unknown effects of underlying conditions (age, rate of bone turnover, or disease affliction) may influence bone healing; and (5) differences in dosing duration and levels between experimental animal models and clinical applications should be considered.
CYCLOOXYGENASES IN THE EYE
COX-1 and COX-2 Expression in the Eye
The COX-1 isoenzyme is expressed in a variety of ocular tissues, and this expression is variable among different animal species (Tables 4 and 5 ). The COX-2 isoenzyme is not generally expressed in normal ocular tissues but is up-regulated during pathologic conditions (Table 5) . COX-2 expression is increased with ocular inflammation or ocular injury (Radi and Render 2008) .
Effects of COX Inhibitors on the Eye
Topically applied ns-NSAIDs (e.g., diclofenac, flurbiprofen, ketorolac, suprofen, indomethacin) inhibit COX-1 and COX-2 and are used in the management of various ophthalmic conditions such as seasonal allergic conjunctivitis; photophobia and pain after corneal refractive surgery; postoperative inflammation after cataract surgery; postoperative topical analgesia; prevention and treatment of cystoid macular edema; and prophylaxis of surgical miosis (Frucht and Zauberman 1984; Gaynes and Fiscella 2002; Sakamoto et al. 1995; Schalnus et al. 2003; Takahashi et al. 2003) . In veterinary medicine, systemic ns-NSAIDs (e.g., carprofen and flunixin meglumine) are used to treat uveal conditions (Giuliano 2004) . Intravenous (i.v.) administration of flunixin meglumine significantly limited miosis and reduced the production of PGE 2 in the aqueous humor after acute inflammation induction in dogs (Millichamp et al. 1991) . In diabetic dogs, sulindac decreased retinal capillary basement membrane thickening and diabetic retinopathy (Gardiner et al. 2003) . In nonhuman primates, continuous infusion of indomethacin into the vitreous cavity reduced vascular leakage (Sakamoto et al. 1995) . Topically applied indomethacin reduced uveitis in rabbits (Yamauchi et al. 1979 ) and markedly inhibited the breakdown of the blood aqueous barrier after paracentesis or argon-laser photocoagulation of the iris in rabbits (van Delft et al. 1987) . In rabbits, intravitreal administration of high doses of diclofenac (300 µg) and ketorolac (3000 µg) were well tolerated and safe, as demonstrated by electroretinographic and histopathologic examination (Kim et al. 2008) . However, topical ophthalmic ns-NSAIDs can lead to local irritations that result in transient burning, stinging, conjunctival hyperemia, and corneal anesthesia (Schalnus et al. 2003) . In addition, indolent corneal ulceration and full-thickness corneal melt can be serious complications associated with the use of topical ns-NSAIDs (Gaynes and Fiscella 2002) . COX-2 s-NSAIDs (e.g., celecoxib, firocoxib, rofecoxib, lumiracoxib, valdecoxib), which spare COX-1 and inhibit only COX-2, have an effect on ocular angiogenesis. For example, rofecoxib attenuates retinal angiogenesis that accompanies retinopathy of prematurity in a mouse model (Wilkinson-Berka et al. 2003) . Celecoxib inhibits retinal VEGF expression and vascular leakage in diabetic rats (Ayalasomayajula and Kompella 2003) . In addition, in diabetic rat retinas, PGE 2 expression was significantly inhibited by celecoxib, indicating the potential value of using celecoxib to treat diabetic retinopathy . In a rat model of angiogenesis, corneal blood vessel formation was suppressed by celecoxib, but not by a selective COX-1 inhibitor (Masferrer et al. 2000) , which suggests that s-NSAIDs such as celecoxib and rofecoxib have an anti-angiogenic response (Takahashi et al. 2004) .
Pathophysiologic Role of Cyclooxygenases in the Eye
Eicosanoids that are present in inflamed tissues are thought to play a significant role in angiogenesis (Yamada et al. 1999) . COX-2 and vascular endothelial growth factor (VEGF) affect vascular permeability and angiogenesis and may be induced by hyperglycemia and tissue hypoxia (Bonazzi et al. 2000; Wilkinson-Berka 2004) . Inhibition of COX-2 has been associated with attenuating angiogenesis and downregulating VEGF and bFGF (Masferrer et al. 1999) . COX-2 s-NSAIDs appear to have great potential in inhibiting corneal angiogenesis and treating diabetic retinopathy and in intravitreal neovascularization associated with ischemic proliferative retinopathy (Sennlaub et al. 2003) . Diabetic individuals are usually susceptible to diabetic retinopathy, which could lead to blindness because of retinal neovascularization . VEGF is markedly increased in the diabetic retina, in age-related macular degeneration (ARMD), and in corneal neovascularization (Adamis et al. 1994; Adamis et al. 2002; Aiello et al. 1994; Cursiefen et al. 2000; Lopez et al. 1996) . Increased PGE 2 can lead to up-regulation of VEGF, which is responsible for the initiation of diabetic retinopathy (Cheng et al. 1998; Frank 2004) . Vascular hyperpermeability and neovascularization lead to vision loss in various ocular pathologies such as diabetic retinopathy and ARMD (Castro et al. 2004) . Elevated VEGF expression is correlated with diabetic blood-retinal barrier breakdown and ischemia-related neovascularization in animal models and humans (Adamis 2002) . Therefore, selective COX-2 inhibition in the eye can have great benefit in attenuation of angiogenesis in various pathological conditions in humans and in animal models. Table 6 summarizes the comparative microanatomic renal expression of COX-1 and COX-2 in various species (Khan et al. 1998) . COX-1 is the most abundant isoform of COX in the kidney and is regionally localized in the renal vasculature, collecting ducts, and papillary interstitial cells across various species (Khan et al. 1998; Radi and Ostroski 2007; Sellers et al. 2004) . COX-2 is minimally expressed in variable locations in the kidney across species (Khan et al. 1998 ). Interspecies differences may exist for the involvement of COX-2 in the generation of renal PGs in states of normal and altered kidney function (Khan and Alden 2002) . COX-2 levels also differ according to maturation, with high levels expressed in the macula densa and thick ascending limbs of fetal kidneys and minimal expression upon renal maturation (Khan and Alden 2002) .
CYCLOOXYGENASES IN THE KIDNEY
COX-1 and COX-2 Expression in the Kidney
Effects of COX Inhibitors on the Kidney
COX-derived prostanoids act in an autocrine or paracrine fashion, exert complex and diverse functions, and serve as physiological buffers within the kidney (Hao and Breyer 2008) . COX-derived prostanoids can modulate renal blood flow (RBF) and glomerular filtration rate (GFR). Modulation of renal physiology is driven by COX-2 catalysis from AA of PGE 2 and PGI 2 ; both are important PGs for the maintenance of RBF. COX-2-deficient mice exhibited severe disruption of renal development and function (Dinchuk et al. 1995; Morham et al. 1995) . COX-2 metabolites have been implicated to play a role in regulation of sodium excretion, renin release, and maintenance of RBF. A high-salt diet markedly increases renal medullary COX-2 expression (Yang et al. 1998) . The importance of renal medullary COX-2 in promoting natriuresis and maintaining blood pressure during high dietary sodium intake has been demonstrated in rats after intramedullary infusion with NS-398, an s-NSAID (Zewde and Mattson 2004) . In preclinical safety studies with celecoxib, transient sodium retention was reported in rats up through six weeks of treatment . Rofecoxib elevated blood pressure in rats fed a normal or high-salt diet (Hocherl et al. 2002) . In rats infused with NS-398, a COX s-NSAID inhibitor, the natriuretic response to increased renal interstitial hydrostatic pressure, induced by direct renal interstitial volume expansion, was preserved (Gross et al. 1999) . Celecoxib failed to alter blood pressure in hypertensive rats, and it is suggested that the natriuretic response to increased blood pressure may be preserved during COX-2 s-NSAID administration (Richter et al. 2004) . In another study, celecoxib resulted in elevated blood pressure in normotensive rats and N-nitro-L-arginine methyl ester (L-NAME)-induced hypertensive rats (Muscara et al. 2000) . The reasons for the differences between studies are unclear, but several hypotheses are proposed: (1) inhibition of carbonic anhydrase, leading to a diuretic action that partially offsets blood pressure elevations in the kidney; and (2) differences in the metabolization of the COX-2 s-NSAID.
Prostanoids also play an important role in blood pressure modulation, and PGs contribute to portal hypertension. Therefore, it is not surprising that both COX-1 and COX-2 blockades reduce portal pressure and visceral blood flow volume of the portal vein and gastric mucosa in rats (Tsugawa et al. 1999) . Nimesulide administration in rats increased arterial pressure and decreased RBF and urine flow rate during low sodium intake (Rodriguez et al. 2000) . Nimesulide resulted in a larger decrease in mean arterial pressure in hypertensive rats than in normotensive rats and decreased GFR and RPF in hypertensive rats, but did not alter GFR or RPF in normotensive rats (Opay et al. 2006) . NS-398, a COX-2 s-NSAID inhibitor, improved portal hypertension and proteinuria in rats without inducing gastric mucosal injury (Tomida et al. 2003; Tsugawa et al. 1999 ). Another experimental COX-2 s-NSAID inhibitor, MF-tricyclic, had no effect on blood pressure in normal and volume-depleted dogs (Black et al. 1998 ). However, blood pressure was moderately elevated in dogs treated with nimesulide, a COX-2 s-NSAID, after intravenous infusion of glucose (Brands et al. 2001) .
PGs also play a role in renal pathophysiology by modulating the release of renin. The macula densa in the kidney is involved in regulating afferent arteriolar tone and renin release by sensing alterations in luminal chloride (Persson et al. 1991) . Low plasma renin levels have been demonstrated in COX-2-deficient mice (Kim et al. 2007 ). It has been demonstrated that COX-2 s-NSAIDs can significantly decrease plasma renin levels and blood pressure in rats (Cheng et al. 2001; Wang et al. 1999) . Rats, and to a lesser extent dogs, can develop renal papillary necrosis (RPN) after ns-NSAID treatment ( Figure 5 ). These species usually exhibit greater susceptibility than humans to RPN nephrotoxicity (Khan and Alden 2002) . It has been speculated that the papillae of rats and dogs are susceptible to chemical injury owing to sluggish blood flow that predisposes to ischemia and accumulation of toxic substances .
Pathophysiologic Role of Cyclooxygenases in the Kidney
The most common renal side effects of ns-NSAIDs are functional and include interference with fluid and electrolyte homeostasis. Other less frequent side effects include acute renal failure, interstitial nephritis, nephritic syndrome, atrophy of subcapsular cortex in dogs, and RPN (Khan and Alden 2002; Khan et al. 2000) . Several potential mechanisms of the effects of ns-NSAIDs on renal pathophysiology have been proposed. These mechanisms include: (1) inhibition of COX, which reduces systemic and renal PG synthesis (Meade et al. 1993; Wen 1997) ; (2) inhibition of PGs by NSAIDs counteracting the hypotensive effects of ACE-I, which blocks ACE and successively increases bradykinin levels, allowing increased renal release of vasodilatory and natriuretic PGs (Blumberg et al. 1977; Linz et al. 1995) ; (3) alterations in systemic vascular resistance and cardiac output (de Leeuw 1996) ; and (4) alterations in the renin-angiotensin-aldosterone system (Houston 1991; Lopez-Ovejero et al. 1978; Sahloul et al. 1990; Wen 1997) . It should be noted that aldosterone can promote endothelial dysfunction independent of blood pressure through COX-2-derived PGI 2 vasoconstriction in both normotensive and hypertensive conditions in rats (Blanco-Rivero et al. 2005 ).
Both COX-2 s-NSAIDs and ns-NSAIDs could contribute to increased blood pressure and edema resulting from RBF and fluid retention imbalance. ns-NSAIDs may aggravate hypertension, and this effect could be related to various mechanisms: (1) altered PG synthesis, (2) altered vascular resistance, and (3) altered renin-angiotensin-aldosterone axis. SUMMARY COX inhibition has varied pathophysiological roles in different tissues and animals that can translate into different outcomes owing to inhibition from ns-and s-NSAIDs. In an extensive evaluation of COX inhibition in GI and in the musculoskeletal, ocular, and renal systems, the following outcomes were seen: (1) COX-2 s-NSAIDs have an improved GI tolerability profile when compared to ns-NSAIDs; (2) preclinical models reveal that effects of COX-2 s-NSAIDs and nsNSAIDs on bone, tendon, and ligament healing are variable; (3) COX-2 s-NSAIDs and ns-NSAIDs have generally beneficial effects in the ocular system; and (4) some COX inhibition renal effects, such as handling of electrolytes, can be predicted from preclinical animal models.
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